CompletedInterventionalPhase 3Last updated Jun 14, 2021

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer

Overview

ClinicalTrials.gov ID: NCT03739684
Lead Sponsor: Progenics Pharmaceuticals, Inc.INDUSTRY
Brief Summary: This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Nov 27, 2018Actual
Primary Completion Date: Aug 29, 2019Actual
Completion Date: Aug 29, 2019Actual

Study Record Dates

First Submitted: Nov 9, 2018
First Submitted that Met QC Criteria: Nov 9, 2018
First Posted: Nov 14, 2018Actual
Last Update Submitted that Met QC Criteria: Jun 10, 2021
Last Update Posted: Jun 14, 2021Actual
Last Verified: Jun 2021

NCT04734184Unknown status

A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

NCT03824275Active, not recruiting

18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

NCT04700332Recruiting

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

NCT03800784Withdrawn

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

NCT03181867Active, not recruiting

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT04727736Terminated

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer